Alzheimer's disease (AD) is an age-related dementia, with the pathological hallmarks of neuritic plaques and neurofibrillary tangles, brain atrophy and loss of synaptic terminals. Dysfunctional mitochondrial bioenergetics is implicated as a contributing factor to the cognitive decline observed in AD. We hypothesized that, in the presence of the AD neurotoxic peptide beta-amyloid, mitochondrial respiration is impaired early in synaptic terminals, which are vital to cognitive performance, preferentially in cognitive centers of the brain. We compared oxygen consumption in synaptosomal and perikaryal mitochondria prepared from the cerebral cortex and cerebellum of wild type (WT) and AD transgenic Tg2576 mice. Compared to WT mice, Tg2576 mice showed decreased mitochondrial respiration in the cerebral cortex specifically in synaptosomal fraction, while the perikaryal mitochondria were unaffected. Neither mitochondrial fraction was affected in the cerebellum of Tg2576 mice as compared to WT. The occurrence of a bioenergetic defect in synaptic terminals of mice overexpressing mutant beta-amyloid, in particular in an area of the brain important to cognition, points to an early role of mitochondrial defects in the onset of cognitive deficits in AD.
Brain imaging studies have shown regionspecific decrease in glucose utilization in Alzheimer's disease (AD) as compared to healthy brains [1, 2] . Lower activities of the mitochondrial tricarboxylic acid cycle enzymes, alpha-ketoglutarate dehydrogenase complex [3, 4] and pyruvate dehydrogenase [5, 6] and of the electron transport chain complex cytochrome c oxidase or complex IV [7] [8] [9] [10] have been reported in AD brains. These findings have led to the hypothesis that defective mitochondrial metabolism may be a cause of AD neurodegeneration [11] .
Recent studies reported that brain mitochondrial function declines in a triple transgenic AD mouse model prior to the onset of amyloid plaque pathology [12] and that synaptic mitochondria are more affected than non-synaptic mitochondria in cognitively impaired AD transgenic mice [13] .
We hypothesized that the early bioenergetic defect may develop preferentially in cognitive areas of the brain, specifically in synaptic mitochondria, in cognitively normal AD mice.
To test this hypothesis, we used the Tg2576 mouse model of AD, which expresses human amyloid precursor protein (APP) with the Swedish double mutation K670N, M671L. This model is characterized by the onset of cognitive decline by the age of 9 months, associated with increased levels of beta-amyloid (Aβ) peptides in the brain [14] .
For preparation of synaptosomal and perikaryal mitochondria, cerebral cortex and cerebellum from female C57B6/SJL wildtype (WT, n=20, 5-15 month old) and pre- For analysis of respiration, synaptic terminals were resuspended in KCl respiration buffer (125 mM KCl, 0.1% BSA, 20 mM HEPES, 2 mM MgCl , 2.5 mM KH 2 PO 4 , pH 7.2) and attached to the Seahorse V7 cell plate at 10 µg protein per well by centrifugation at 3,220 x g for 1 h at 4°C.
Oxygen consumption rate (OCR) in synaptic terminals was measured using the Seahorse Schematic figure showing the substrates, uncoupler and inhibitors used in the OCR analysis and the steps of the oxidative phosphorylation pathway where they act. Clockwise from the top: pyruvate and malate enter the tricarboxylic acid (TCA) cycle and provide NADH to complex I of the electron transport chain; ADP provides the substrate for phosphorylation at complex V; oligomycin inhibits complex V and thence oxidation; p-trifluoromethoxy carbonyl cyanide phenyl hydrazone (FCCP) uncouples oxidation from phosphorylation by releasing the proton gradient across the mitochondrial inner membrane and leading to maximal OCR; ascorbate and N,N,N' ,N'-tetramethyl-p-phenylenediamine (TMPD) act as artificial electron donors for complex IV; antimycin and rotenone inhibit complexes III and I respectively. Expression level of VDAC1 in (A) synaptosomal fractions and (B) perikaryal mitochondria prepared from cerebral cortex of WT and Tg2576 mice were examined by Western blots using anti-VDAC1 antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). Data are represented as mean ± SEM of 3-7 replicates in arbitrary units (AU). The insets show representative Western blots for VDAC1. No significant difference was detected as assessed by two-tailed t test. [18] . Additionally we show the presence of the synaptic mitochondrial defect specifically in the cerebral cortex, but not the cerebellum, prior to the onset of cognitive deficits in Tg2576 mice [14] . While an earlier study had shown a synaptic bioenergetic deficit in the cortex, hippocampus, striatum and amygdala, but not the cerebellum, of Tg2576 mice at 12 months of age [13] , our results demonstrate that the synaptic mitochondrial defect is manifest at an age when the mice are reported cognitively intact.Co-localization of Aβ [19] and APP [20] with brain mitochondria has been reported in AD and in Tg2576 [21, 22] . Both Aβ 1-40 and Aβ 1-42 forms were found in mitochondria from Tg2576 cortex [22] , with preferential Aβ accumulation in the synaptic mitochondria of 12 month old Tg mAPP mice [18] . Aβ in the presence of copper specifically inhibited complex IV activity in isolated mitochondria [21] . While amyloid plaques are not detected in 5-8 month old Tg2576, soluble forms of Aβ, such as the oligomers found in our study, may inhibit mitochondrial respiration in synapses and set in motion the loss of synapses and subsequent cognitive decline observed at a later age [23] .
Our results in Tg2576 mice indicate that bioenergetic deficits in the synaptic terminals in cognitive centers of the brain precede and may contribute to the onset of cognitive dysfunction in AD, providing a target for early therapy.
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